Anastro-K1 1 - Kassel Pharma

In the landscape of hormonal therapy, anastrozole emerged in 1995 as a game-changing innovation from Zeneca Pharmaceuticals. Unlike earlier treatments, it reduced estrogen levels by directly inhibiting aromatase, not just blocking its receptors. Its rise to prominence was catalyzed by the extensive ATAC trial, which compared it to tamoxifen and highlighted its superior long-term outcomes. These findings helped reorient clinical practice in favor of aromatase inhibitors for treating postmenopausal breast cancer.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Anastro-K1 1 by Kassel Pharma, consult with your doctor or healthcare professional.